Dr. Yixing Jiang, MD

Dr. Jiang practices at Memorial Health System of Southwest Oklahoma in Lawton, Oklahoma, part of Memorial Health System of Southwest Oklahoma.

Dr. Jiang's NPI, 1720037971, was assigned on May 8, 2006. Dr. Jiang holds Maryland license D74582.

Dr. Jiang's primary practice is Memorial Health System of Southwest Oklahoma, at 3401 West Gore Blvd, Lawton, OK 73505 in Comanche County. The practice phone is (580) 355-8620.

Dr. Jiang's primary practice is Memorial Health System of Southwest Oklahoma in Lawton, Oklahoma, part of Memorial Health System of Southwest Oklahoma. Dr. Jiang is also affiliated with Penn State Health Milton S. Hershey Medical Center. The medical group on file is Cancer Centers of Southwest Oklahoma. Dmand AI also links Dr. Jiang to 3 more hospitals, 2 medical groups, 1 community health center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jiang practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Jiang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Jiang's licenses on file in 2 states: Maryland and Pennsylvania.

CMS data shows 625 Medicare services from Dr. Jiang across 6 procedure codes in 2024, for 161 Medicare patients. Medicare paid $48,356 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 161 Medicare patients who saw Dr. Jiang in 2024. The largest group is 65 to 74, with 90 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jiang's median patient age at 67, with 51% women.

In 2024, Dr. Jiang wrote 382 Medicare Part D claims for 64 patients. 78% of them were for generic drugs. CMS names the drug for 256 of them, across 11 drugs with 11 or more claims each, at $391,632 in total drug cost. In 2023, CMS named 199 claims across 6 drugs.

Dr. Jiang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jiang as offering telehealth.

Dmand AI links 35 papers to Dr. Jiang, published from 2009 to 2025. 2014 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Liver Neoplasms and Carcinoma, Hepatocellular. Dr. Jiang has published most often in Cancer Chemother Pharmacol. Dr. Jiang's most frequent co-authors are Jaffer A. Ajani, MD, Chandra P. Belani, MD and Niraj Jaysukh Gusani, MD.

Dmand AI links Dr. Jiang to 10 clinical trials, 3 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Gallbladder Neoplasms. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 44 general payments to Dr. Jiang from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Eisai Inc. paid the most, $5,930.